Collaboration aims to accelerate the development of treatments for chronic kidney disease (CKD) and other conditions Rectify ...

Rectify Pharmaceuticals has entered a strategic research and licensing agreement with Boehringer Ingelheim to accelerate the ...

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Edwards Lifesciences today announced the company's SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach to receive U.S. Food and Drug ...

Clinicians discuss the rapidly evolving therapies, technology, and surgical approaches for early-stage NSCLC and take a fresh look at the future of care. Teamwork: A Multidisciplinary Approach to ...

Peripheral ossifying fibroma (POF) is a benign, reactive lesion that most commonly arises on the gingiva. Characterised by a fibrocellular proliferation with variable deposition of calcified material ...